Duvelisib reduced primary AML blast survival with increasing concentrations, and AML samples were sensitive at 1000nM. In DB cells, Duvelisib substantially attenuated IKK and IκBα phosphorylation, with greater potency against IκBα. In Mlg cells without TGF‐β1 stimulation, Duvelisib showed a half-maximal inhibitory concentration of 12.94 μM at 24 h in the MTT cytotoxicity test. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Duvelisib effects on primary AML cells
Cell-based study · primary AML cells [1]
Primary AML cells showed reduced blast survival with increasing Duvelisib concentrations. AML samples were sensitive at 1000nM, with colonies visualised, measured and counted after 10 days.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1000nM
- Exposure duration
- after 10 days
- Reported limits
- Not stated in the sentences used: route, vehicle, control.
Methods and source locations
Compound reported in the paper: Duvelisib; Compound label in the paper: IPI 145
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > PI3K inhibition reduces the survival of AML blasts (S12, S14); MATERIALS AND METHODS > Methods > Clonogenic methylcellulose assays (S77); Figure 1 legend (S114)
number of colonies: number of colonies — RESULTS > PI3K inhibition reduces the survival of AML blasts (S12, S14); MATERIALS AND METHODS > Methods > Clonogenic methylcellulose assays (S77); Figure 1 legend (S114)
Attenuated IKK and IκBα Phosphorylation in DB Cells
Cell-based study · DB cells [2]
In DB cells, Duvelisib substantially attenuated phosphorylation of both IKK and IκBα, with greater potency against IκBα.
Literature-Reported Treatment Conditions
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: dose, route, schedule.
Methods and source locations
Compound reported in the paper: Duvelisib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Result > Duvelisib and chidamide stabilize IκBα in the cytoplasm through selective targeting of PI3K delta and HDAC2 (S55); Fig. 5 legend (S216, S220)
protein expression levels of IKKα/β, p-IKKα/β (Ser176/180), IκBα and p-IκBα (Ser32): protein expression levels of IKKα/β, p-IKKα/β (Ser176/180), IκBα and p-IκBα (Ser32); comparator: DMSO — Result > Duvelisib and chidamide stabilize IκBα in the cytoplasm through selective targeting of PI3K delta and HDAC2 (S55); Fig. 5 legend (S216)
Duvelisib cytotoxicity in Mlg cells
Cell-based study · Mlg cells [3]
Cytotoxicity test of Mlg cells (MTT), without TGF‐β1 stimulation. Mlg cells were exposed to the indicated doses of Duvelisib for 24 h, IC50 = 12.94 μM.
Literature-Reported Treatment Conditions
- Exposure duration
- 24 h
- Method
- exposed
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Duvelisib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Duvelisib suppresses TGF‐β1‐induced proliferation of lung fibroblasts (S82, S83); FIGURE 2 legend (S135, S136, S143)
Cytotoxicity test of Mlg cells (MTT): Cytotoxicity test of Mlg cells (MTT); comparator: control group — RESULTS > Duvelisib suppresses TGF‐β1‐induced proliferation of lung fibroblasts (S82, S83); FIGURE 2 legend (S135, S136)